Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart

PurposeThe glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is associated with a reduction of angiotensin (Ang) II-induced cardiac fibrosis.Methods and ResultsSprague–Dawley rats were subjected to Ang II (500 ng/kg/min) infusion using osmotic minipumps for 4 weeks. Liraglutide (0.3 mg/kg) was subcutaneously injected twice daily or linagliptin (8 mg/kg) was administered via oral gavage daily during Ang II infusion. Relative to the control, liraglutide, but not linagliptin decreased MAP (124 ± 4 vs. 200 ± 7 mmHg in control, p < 0.003). Liraglutide and linagliptin comparatively reduced the protein level of the Ang II AT1 receptor and up-regulated the AT2 receptor as identified by a reduced AT1/AT2 ratio (0.4 ± 0.02 and 0.7 ± 0.01 vs. 1.4 ± 0.2 in control, p < 0.05), coincident with the less locally-expressed AT1 receptor and enhanced AT2 receptor in the myocardium and peri-coronary vessels. Both drugs significantly reduced the populations of macrophages (16 ± 6 and 19 ± 7 vs. 61 ± 29 number/HPF in control, p < 0.05) and α-SMA expressing myofibroblasts (17 ± 7 and 13 ± 4 vs. 66 ± 29 number/HPF in control, p < 0.05), consistent with the reduction in expression of TGFβ1 and phospho-Smad2/3, and up-regulation of Smad7. Furthermore, ACE2 activity (334 ± 43 and 417 ± 51 vs. 288 ± 19 RFU/min/μg protein in control, p < 0.05) and GLP-1 receptor expression were significantly up-regulated. Along with these modulations, the synthesis of collagen I and tissue fibrosis were inhibited as determined by the smaller collagen-rich area and more viable myocardium.ConclusionThese results demonstrate for the first time that preservation of GLP-1 using liraglutide or linagliptin is effective in inhibiting Ang II-induced cardiac fibrosis, suggesting that these drugs could be selected as an adjunctive therapy to improve clinical outcomes in the fibrosis-derived heart failure patients with or without diabetes.

[1]  B. Hocher,et al.  The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. , 2013, International journal of cardiology.

[2]  F. Jamali,et al.  Inflammation Alters Angiotensin Converting Enzymes (ACE and ACE-2) Balance in Rat Heart , 2011, Inflammation.

[3]  M. Black,et al.  Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. , 2004, Journal of molecular and cellular cardiology.

[4]  C. Anderson,et al.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure , 2010, Cardiovascular diabetology.

[5]  N. Frangogiannis,et al.  The role of TGF-β Signaling in Myocardial Infarction and Cardiac Remodeling , 2007 .

[6]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[7]  D. Dutka,et al.  Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1 , 2014, Cardiovascular Diabetology.

[8]  S. Yuan,et al.  Cardiac pathologies in relation to Smad-dependent pathways. , 2010, Interactive cardiovascular and thoracic surgery.

[9]  D. Wootten,et al.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation , 2014, British journal of pharmacology.

[10]  D. Stiller,et al.  Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity , 2012, PloS one.

[11]  J. Mehta,et al.  Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation , 2013, Cardiovascular Drugs and Therapy.

[12]  I. Dixon,et al.  Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. , 2000, American journal of physiology. Heart and circulatory physiology.

[13]  Antony Vinh,et al.  AT2 receptors: Functional relevance in cardiovascular disease , 2008, Pharmacology & Therapeutics.

[14]  M. Mocanu,et al.  Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner , 2013, Cardiovascular Diabetology.

[15]  Hui-Hua Li,et al.  Angiotensin II Infusion–Induced Inflammation, Monocytic Fibroblast Precursor Infiltration, and Cardiac Fibrosis are Pressure Dependent , 2011, Cardiovascular Toxicology.

[16]  M. Fujii,et al.  Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis , 2014, Medical Molecular Morphology.

[17]  K. Weber.  Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. , 2004, Journal of hypertension.

[18]  S. Keidar,et al.  ACE2 of the heart: From angiotensin I to angiotensin (1-7). , 2007, Cardiovascular research.

[19]  R. Shannon,et al.  Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. , 2005, American journal of physiology. Heart and circulatory physiology.

[20]  C. Ram.  Angiotensin receptor blockers: current status and future prospects. , 2008, The American journal of medicine.

[21]  M. Raizada,et al.  Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). , 2007, American journal of physiology. Heart and circulatory physiology.

[22]  S. Ravassa,et al.  GLP-1 and cardioprotection: from bench to bedside. , 2012, Cardiovascular research.

[23]  M. Sortino,et al.  Linagliptin: A thorough Characterization beyond Its Clinical Efficacy , 2013, Front. Endocrinol..

[24]  J. Mehta,et al.  DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway , 2014, Cardiovascular Drugs and Therapy.

[25]  Ningping Wang,et al.  Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction , 2012, British journal of pharmacology.

[26]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[27]  T. Unger,et al.  AT2 Receptor and Tissue Injury: Therapeutic Implications , 2014, Current Hypertension Reports.

[28]  H. Woerle,et al.  Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme , 2012, Cardiovascular Diabetology.

[29]  Stephen C. Jones,et al.  Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. , 2007, American journal of physiology. Heart and circulatory physiology.

[30]  R. Henkelman,et al.  Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009 .

[31]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[32]  S. Solomon,et al.  Angiotensin II receptor blockade and ventricular remodelling , 2005, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[33]  S. Ito,et al.  Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. , 2005, American journal of physiology. Endocrinology and metabolism.

[34]  J. Heger,et al.  www.elsevier.com/locate/cardiores Review The complex pattern of SMAD signaling in the cardiovascular system B , 2005 .

[35]  G. Oudit,et al.  Cardioprotective Effects Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin 1-7 in Experimental Heart Failure in Angiotensin-Converting Enzyme 2–Null Mice , 2012, Hypertension.

[36]  Matthew J. Crowley,et al.  Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. , 2012, American heart journal.

[37]  L. B. Knudsen.  Liraglutide: the therapeutic promise from animal models , 2010, International journal of clinical practice. Supplement.

[38]  G. Remuzzi,et al.  Angiotensin II revisited: new roles in inflammation, immunology and aging , 2010, EMBO molecular medicine.

[39]  T. Ogihara,et al.  Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload–Induced Cardiac Dysfunction by Increasing Local Angiotensin II , 2006, Hypertension.

[40]  C. Anderson,et al.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure , 2010, Cardiovascular diabetology.

[41]  J. Ménard,et al.  Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists , 2004, Circulation.

[42]  D. Diz,et al.  Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. , 2007, American journal of physiology. Heart and circulatory physiology.

[43]  Z. Zuo,et al.  Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. , 2009, European journal of pharmacology.

[44]  M. Mocanu,et al.  Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway , 2007, Cardiovascular Drugs and Therapy.

[45]  N. Marx,et al.  Repair after myocardial infarction, between fantasy and reality: the role of chemokines. , 2011, Journal of the American College of Cardiology.

[46]  Yuejin Yang,et al.  The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives , 2013, Cardiovascular Drugs and Therapy.

[47]  C. Ram,et al.  Angiotensin receptor blockers: current status and future prospects. , 2007, Indian heart journal.